HK1010888A1 - Cell adhesion inhibitors - Google Patents
Cell adhesion inhibitorsInfo
- Publication number
- HK1010888A1 HK1010888A1 HK98112181A HK98112181A HK1010888A1 HK 1010888 A1 HK1010888 A1 HK 1010888A1 HK 98112181 A HK98112181 A HK 98112181A HK 98112181 A HK98112181 A HK 98112181A HK 1010888 A1 HK1010888 A1 HK 1010888A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cell adhesion
- adhesion inhibitors
- inhibitors
- cell
- adhesion
- Prior art date
Links
- 230000021164 cell adhesion Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06104—Dipeptides with the first amino acid being acidic
- C07K5/06113—Asp- or Asn-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/498,237 US6248713B1 (en) | 1995-07-11 | 1995-07-11 | Cell adhesion inhibitors |
PCT/US1996/011570 WO1997003094A1 (en) | 1995-07-11 | 1996-07-11 | Cell adhesion inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1010888A1 true HK1010888A1 (en) | 1999-07-02 |
Family
ID=23980177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK98112181A HK1010888A1 (en) | 1995-07-11 | 1998-11-20 | Cell adhesion inhibitors |
Country Status (28)
Country | Link |
---|---|
US (2) | US6248713B1 (cs) |
EP (1) | EP0842196B1 (cs) |
JP (2) | JPH11511124A (cs) |
KR (1) | KR100531586B1 (cs) |
CN (1) | CN1195778C (cs) |
AU (1) | AU716276B2 (cs) |
BG (1) | BG63876B1 (cs) |
BR (1) | BR9609782A (cs) |
CA (1) | CA2226868A1 (cs) |
CZ (1) | CZ299054B6 (cs) |
DE (1) | DE69637328T2 (cs) |
EA (2) | EA001594B1 (cs) |
EE (2) | EE200200384A (cs) |
FI (1) | FI980033A (cs) |
HK (1) | HK1010888A1 (cs) |
HU (1) | HUP9802202A3 (cs) |
IL (1) | IL122783A (cs) |
IS (1) | IS4648A (cs) |
MX (1) | MX9800348A (cs) |
NO (1) | NO980097L (cs) |
NZ (1) | NZ312950A (cs) |
PL (1) | PL188446B1 (cs) |
RO (1) | RO121032B1 (cs) |
SK (1) | SK3798A3 (cs) |
TR (1) | TR199800028T1 (cs) |
TW (1) | TW570927B (cs) |
UA (1) | UA71888C2 (cs) |
WO (1) | WO1997003094A1 (cs) |
Families Citing this family (131)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6248713B1 (en) * | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
US6037324A (en) * | 1996-01-04 | 2000-03-14 | Leukosite, Inc. | Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor |
US6686350B1 (en) | 1996-07-25 | 2004-02-03 | Biogen, Inc. | Cell adhesion inhibitors |
DE69737769T2 (de) | 1996-07-25 | 2008-05-15 | Biogen Idec Ma Inc., Cambridge | Molekülmodell für vla-4-inhibitoren |
US6221888B1 (en) | 1997-05-29 | 2001-04-24 | Merck & Co., Inc. | Sulfonamides as cell adhesion inhibitors |
US6291511B1 (en) | 1997-05-29 | 2001-09-18 | Merck & Co., Inc. | Biarylalkanoic acids as cell adhesion inhibitors |
US6903075B1 (en) | 1997-05-29 | 2005-06-07 | Merck & Co., Inc. | Heterocyclic amide compounds as cell adhesion inhibitors |
ES2257808T3 (es) * | 1997-05-29 | 2006-08-01 | MERCK & CO., INC. (A NEW JERSEY CORP.) | Acidos biarilalcanoicos como inhibidores de adhesion celular. |
US6093696A (en) * | 1997-05-30 | 2000-07-25 | Celltech Therapeutics, Limited | Tyrosine derivatives |
US6492421B1 (en) | 1997-07-31 | 2002-12-10 | Athena Neurosciences, Inc. | Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
AR016133A1 (es) * | 1997-07-31 | 2001-06-20 | Wyeth Corp | Compuesto de carbamiloxi que inhiben la adhesion de leucocitos mediada por vla-4, compuestos que son prodrogas de dichos compuestos, composicionfarmaceutica, metodo para fijar vla-4 a una muestra biologica, metodo para el tratamiento de una condicion inflamatoria |
US6423688B1 (en) | 1997-07-31 | 2002-07-23 | Athena Neurosciences, Inc. | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6939855B2 (en) * | 1997-07-31 | 2005-09-06 | Elan Pharmaceuticals, Inc. | Anti-inflammatory compositions and method |
US6362341B1 (en) | 1997-07-31 | 2002-03-26 | Athena Neurosciences, Inc. | Benzyl compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6489300B1 (en) | 1997-07-31 | 2002-12-03 | Eugene D. Thorsett | Carbamyloxy compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US7030114B1 (en) | 1997-07-31 | 2006-04-18 | Elan Pharmaceuticals, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6583139B1 (en) | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6291453B1 (en) | 1997-07-31 | 2001-09-18 | Athena Neurosciences, Inc. | 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4 |
US6559127B1 (en) | 1997-07-31 | 2003-05-06 | Athena Neurosciences, Inc. | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
DE19741235A1 (de) | 1997-09-18 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
DE19741873A1 (de) * | 1997-09-23 | 1999-03-25 | Hoechst Marion Roussel De Gmbh | Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
US6069163A (en) * | 1997-10-21 | 2000-05-30 | Merck & Co., Inc. | Azapeptide acids as cell adhesion inhibitors |
AU748041B2 (en) * | 1997-10-31 | 2002-05-30 | Aventis Pharma Limited | Substituted anilides |
GB9723789D0 (en) | 1997-11-12 | 1998-01-07 | Zeneca Ltd | Chemical compounds |
AU1415099A (en) * | 1997-11-18 | 1999-06-07 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
US6020347A (en) * | 1997-11-18 | 2000-02-01 | Merck & Co., Inc. | 4-substituted-4-piperidine carboxamide derivatives |
DE19751251A1 (de) | 1997-11-19 | 1999-05-20 | Hoechst Marion Roussel De Gmbh | Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate |
US6191171B1 (en) | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
US6090841A (en) * | 1997-11-21 | 2000-07-18 | Merck & Co., Inc. | Substituted pyrrole derivatives as cell adhesion inhibitors |
ES2221227T3 (es) * | 1997-11-24 | 2004-12-16 | MERCK & CO., INC. | Derivados sustituidos de beta-alanina como inhibidores de la adhesion celular. |
US6645939B1 (en) | 1997-11-24 | 2003-11-11 | Merck & Co., Inc. | Substituted β-alanine derivatives as cell adhesion inhibitors |
US6407065B1 (en) | 1998-01-23 | 2002-06-18 | Novartis Ag | VLA-4 antagonists |
US6329372B1 (en) | 1998-01-27 | 2001-12-11 | Celltech Therapeutics Limited | Phenylalanine derivatives |
GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
WO1999054321A1 (en) * | 1998-04-21 | 1999-10-28 | Aventis Pharma Limited | Substituted diamines and their use as cell adhesion inhibitors |
DE19821483A1 (de) | 1998-05-14 | 1999-11-18 | Hoechst Marion Roussel De Gmbh | Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
GB9811159D0 (en) | 1998-05-22 | 1998-07-22 | Celltech Therapeutics Ltd | Chemical compounds |
MXPA00011774A (es) | 1998-05-28 | 2002-10-17 | Biogen Inc | Un nuevo inhibidor vla-4: ome pupa-v. |
GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
AU1915399A (en) * | 1998-07-10 | 2000-02-01 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
GB9916374D0 (en) | 1998-07-23 | 1999-09-15 | Zeneca Ltd | Chemical compounds |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9821222D0 (en) | 1998-09-30 | 1998-11-25 | Celltech Therapeutics Ltd | Chemical compounds |
GB9825652D0 (en) | 1998-11-23 | 1999-01-13 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
GB9828074D0 (en) | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
HUP0200481A3 (en) | 1998-12-23 | 2002-12-28 | Aventis Pharma Ltd West Mallin | Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines, process for their preparation and pharmaceutical compositions containing them |
US6407066B1 (en) | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
DE19922462A1 (de) | 1999-05-17 | 2000-11-23 | Aventis Pharma Gmbh | Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
BR0012068A (pt) * | 1999-06-30 | 2002-05-14 | Daiichi Seiyaku Co | Compostos inibidores de vla-4 |
US6756378B2 (en) | 1999-06-30 | 2004-06-29 | Pharmacopeia Drug Discovery, Inc. | VLA-4 inhibitor compounds |
US6630503B1 (en) * | 1999-08-13 | 2003-10-07 | Biogen, Inc. | Cell adhesion inhibitors |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
CA2394431C (en) | 1999-12-16 | 2015-06-30 | Jane Relton | Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
CN1413210A (zh) | 1999-12-28 | 2003-04-23 | 辉瑞产品公司 | 用于治疗炎症、自身免疫性疾病和呼吸系统疾病的vla-4依赖性细胞结合的非肽基抑制剂 |
AU2001248553A1 (en) | 2000-04-17 | 2001-10-30 | Celltech R And D Limited | Enamine derivatives as cell adhesion molecules |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
US6740654B2 (en) | 2000-07-07 | 2004-05-25 | Celltech R & D Limited | Squaric acid derivatives |
JP2004505110A (ja) | 2000-08-02 | 2004-02-19 | セルテック アール アンド ディ リミテッド | 3位置換イソキノリン−1−イル誘導体 |
CA2428753C (en) * | 2000-11-17 | 2013-05-21 | Idenix (Cayman) Limited | Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines |
US6875743B1 (en) | 2000-11-28 | 2005-04-05 | Biogen, Inc. | Cell adhesion inhibitors |
RU2290403C2 (ru) | 2000-12-28 | 2006-12-27 | Дайити Фармасьютикал Ко., Лтд. | Ингибиторы vla-4 |
DE10111877A1 (de) | 2001-03-10 | 2002-09-12 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
GB2377933A (en) | 2001-07-06 | 2003-01-29 | Bayer Ag | Succinic acid derivatives useful as integrin antagonists |
DE10137595A1 (de) | 2001-08-01 | 2003-02-13 | Aventis Pharma Gmbh | Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung |
US6897538B2 (en) * | 2001-08-20 | 2005-05-24 | Honeywell International, Inc. | Micro-machined electromechanical system (MEMS) accelerometer device having arcuately shaped flexures |
AR038136A1 (es) | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
JP2006511500A (ja) | 2002-10-30 | 2006-04-06 | メルク エンド カムパニー インコーポレーテッド | γ−アミノアミド系のケモカイン受容体活性調節剤 |
CA2770493A1 (en) | 2003-07-24 | 2005-02-03 | Daiichi Pharmaceutical Co., Ltd. | Cyclohexanecarboxylic acid compound |
CN1301426C (zh) * | 2003-08-19 | 2007-02-21 | 友达光电股份有限公司 | 窄边框设计的液晶显示面板及其制作方法 |
WO2005066124A1 (ja) * | 2003-12-26 | 2005-07-21 | Daiichi Pharmaceutical Co., Ltd. | ピロリジン誘導体の製造法 |
WO2005122379A2 (en) * | 2004-05-27 | 2005-12-22 | The Regents Of The University Of California | Alpha-4 beta-1 integrin ligands for imaging and therapy |
WO2006004903A2 (en) * | 2004-06-28 | 2006-01-12 | Atherogenics, Inc. | 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof |
US7196112B2 (en) | 2004-07-16 | 2007-03-27 | Biogen Idec Ma Inc. | Cell adhesion inhibitors |
US7140250B2 (en) * | 2005-02-18 | 2006-11-28 | Honeywell International Inc. | MEMS teeter-totter accelerometer having reduced non-linearty |
EP1961750B1 (en) | 2005-12-13 | 2013-09-18 | Daiichi Sankyo Company, Limited | Vla-4 inhibitory drug |
WO2008103378A2 (en) | 2007-02-20 | 2008-08-28 | Merrimack Pharmaceuticals, Inc. | Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist |
CN101970405A (zh) | 2007-12-14 | 2011-02-09 | 普尔马金医疗(哮喘)有限公司 | 吲哚及其治疗用途 |
BRPI0911652A2 (pt) | 2008-04-11 | 2015-08-04 | Merrimack Pharmaceuticals Inc | Ligantes de albumina sérica humana e seus conjugados |
US8637671B2 (en) | 2008-09-22 | 2014-01-28 | Merck Canada Inc. | Indole derivatives as CRTH2 receptor antagonists |
US20100204221A1 (en) | 2009-02-09 | 2010-08-12 | Hariprasad Vankayalapati | Pyrrolopyrimidinyl axl kinase inhibitors |
GB0902648D0 (en) | 2009-02-17 | 2009-04-01 | Argenta Discovery Ltd | Pharmaceutical compounds and compositions |
EA201190119A1 (ru) | 2009-02-17 | 2012-05-30 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38 |
US8394819B2 (en) | 2009-02-24 | 2013-03-12 | Merck Sharp & Dohme Corp. | Indole derivatives as CRTH2 receptor antagonists |
KR20120118008A (ko) * | 2009-12-18 | 2012-10-25 | 아이데닉스 파마슈티칼스, 인코포레이티드 | 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 c 바이러스 억제제 |
GB201009731D0 (en) | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
WO2012031228A2 (en) | 2010-09-02 | 2012-03-08 | The Regents Of The University Of California | Llp2a-bisphosphonate conjugates for osteoporosis treatment |
EP2627178B1 (en) | 2010-10-11 | 2018-05-02 | Merck Sharp & Dohme Corp. | Quinazolinone-type compounds as crth2 antagonists |
AU2011349524B2 (en) | 2010-12-23 | 2016-06-02 | Merck Sharp & Dohme Corp. | Quinoxalines and aza-quinoxalines as CRTH2 receptor modulators |
EP2704571B1 (en) | 2011-05-04 | 2020-04-22 | Merck Sharp & Dohme Corp. | Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors |
US20140128367A1 (en) | 2011-06-17 | 2014-05-08 | Merck Sharp & Dohme Corp. | Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators |
US8987456B2 (en) | 2011-10-05 | 2015-03-24 | Merck Sharp & Dohme Corp. | 3-pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
CN103974953B (zh) | 2011-12-09 | 2016-06-29 | 奇斯药制品公司 | 激酶抑制剂 |
HUE029826T2 (en) | 2011-12-09 | 2017-04-28 | Chiesi Farm Spa | Kinase Inhibitors |
KR20140103925A (ko) | 2011-12-09 | 2014-08-27 | 키에시 파르마슈티시 엣스. 피. 에이. | 4-히드록시-1,2,3,4-테트라히드로나프탈렌-1-일 우레아 및 호흡기 질환의 치료에서의 이들의 용도 |
BR112015029970A2 (pt) | 2013-06-06 | 2017-07-25 | Chiesi Farm Spa | inibidores de cinase |
CN104817615A (zh) * | 2014-01-30 | 2015-08-05 | 陈光健 | 寡肽cd05及其制备方法和应用 |
CN104817625A (zh) * | 2014-01-30 | 2015-08-05 | 陈光健 | 寡肽cd03及其制备方法和应用 |
CN104817613A (zh) * | 2014-01-30 | 2015-08-05 | 陈光健 | 寡肽cd06及其制备方法和应用 |
CN104817622A (zh) * | 2014-01-30 | 2015-08-05 | 陈光健 | 寡肽cd04及其制备方法和应用 |
CN105294830A (zh) * | 2014-06-18 | 2016-02-03 | 陈光健 | 一种二肽分子及其制备方法和应用 |
JP7011830B2 (ja) | 2015-10-14 | 2022-01-27 | エックス-サーマ インコーポレイテッド | 氷晶形成を低減するための組成物および方法 |
TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
EP3394060A1 (en) | 2015-12-23 | 2018-10-31 | Chiesi Farmaceutici S.p.A. | 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urea derivatives and their use as p38 mapk inhibitors |
AR107163A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | Inhibidores de quinasa |
AR107165A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | Inhibidores de quinasa |
CN109476638B (zh) | 2016-05-05 | 2021-12-28 | 豪夫迈·罗氏有限公司 | 吡唑衍生物、其组合物及治疗用途 |
SG11201901954XA (en) | 2016-09-06 | 2019-04-29 | Hoffmann La Roche | 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof |
EP3939989A1 (en) | 2016-11-11 | 2022-01-19 | Zealand Pharma A/S | Cyclic peptides multimers targeting alpha 4beta 7 integrin |
CR20190310A (es) | 2016-12-29 | 2019-08-21 | Hoffmann La Roche | Compuestos de pirazolopirimidina y métodos de uso de los mismos |
WO2018140510A1 (en) | 2017-01-25 | 2018-08-02 | Biogen Ma Inc. | Compositions and methods for treatment of stroke and other cns disorders |
CN110494434B (zh) | 2017-03-14 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 吡唑并氯苯基化合物、其组合物及其使用方法 |
EP3621980A4 (en) | 2017-05-10 | 2021-06-30 | Zealand Pharma A/S | HOMODETIC CYCLIC PEPTIDES TARGETING INTEGRIN ALPHA4 BETA7 |
EP3630766A1 (en) | 2017-05-22 | 2020-04-08 | H. Hoffnabb-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
WO2018215390A1 (en) | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
US10364245B2 (en) | 2017-06-07 | 2019-07-30 | Chiesi Farmaceutici S.P.A. | Kinase inhibitors |
WO2019139714A1 (en) | 2018-01-15 | 2019-07-18 | Genentech, Inc. | Pyrazolopyrimidine compounds as jak inhibitors |
CN112969700A (zh) | 2018-10-30 | 2021-06-15 | 吉利德科学公司 | 作为α4β7整合素抑制剂的咪唑并吡啶衍生物 |
CN112969687A (zh) | 2018-10-30 | 2021-06-15 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
JP7189369B2 (ja) | 2018-10-30 | 2022-12-13 | ギリアード サイエンシーズ, インコーポレイテッド | アルファ4β7インテグリンの阻害のための化合物 |
EP3873897A1 (en) | 2018-10-30 | 2021-09-08 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
JP2022517610A (ja) | 2019-01-10 | 2022-03-09 | シーエスピーシー ゾンチー ファーマシューティカル テクノロジー(シージアチュアン)カンパニー,リミテッド | 複素環化合物塩およびその使用 |
US20200399274A1 (en) | 2019-06-18 | 2020-12-24 | Genentech, Inc. | Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof |
BR112021025618A2 (pt) | 2019-06-18 | 2022-02-01 | Hoffmann La Roche | Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto |
JP2022537354A (ja) | 2019-06-18 | 2022-08-25 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Jakキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用 |
WO2021030438A1 (en) | 2019-08-14 | 2021-02-18 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1149971B (it) | 1979-06-11 | 1986-12-10 | Syntex Inc | Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante |
US4725583A (en) | 1985-01-23 | 1988-02-16 | Abbott Laboratories | Functionalized peptidylaminoalcohols |
US4826815A (en) | 1985-05-17 | 1989-05-02 | Abbott Laboratories | Renin inhibiting compounds |
GB2218102B (en) | 1988-04-08 | 1992-09-16 | Sandoz Ltd | Calcitonin peptide derivatives |
EP0506748B1 (en) | 1989-12-22 | 1995-12-13 | Commonwealth Scientific And Industrial Research Organisation | Amino acids, peptides or derivatives thereof coupled to fats |
CA2043741C (en) | 1990-06-07 | 2003-04-01 | Kiyofumi Ishikawa | Endothelin antagonistic peptide derivatives |
US5192746A (en) | 1990-07-09 | 1993-03-09 | Tanabe Seiyaku Co., Ltd. | Cyclic cell adhesion modulation compounds |
US5260277A (en) | 1990-09-10 | 1993-11-09 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
WO1992008464A1 (en) | 1990-11-15 | 1992-05-29 | Tanabe Seiyaku Co. Ltd. | Substituted urea and related cell adhesion modulation compounds |
CA2071674C (en) | 1991-06-21 | 2003-08-19 | Kevin T. Chapman | Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme |
WO1993008823A1 (en) | 1991-11-06 | 1993-05-13 | Tanabe Seiyaku Co., Ltd. | Guanidinyl and related cell adhesion modulation compounds |
US5352667A (en) | 1991-11-22 | 1994-10-04 | Ofer Lider | Non-peptidic surrogates of the Arg-Gly-Asp sequence and pharmaceutical compositions comprising them |
WO1993012809A1 (en) | 1991-12-24 | 1993-07-08 | Fred Hutchinson Cancer Research Center | Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv |
DE4212304A1 (de) | 1992-04-13 | 1993-10-14 | Cassella Ag | Asparaginsäurederivate, ihre Herstellung und Verwendung |
IL102646A (en) | 1992-07-26 | 1996-05-14 | Yeda Res & Dev | Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them |
JPH08505628A (ja) | 1993-01-08 | 1996-06-18 | 田辺製薬株式会社 | ペプチド型細胞接着阻害薬 |
US5314902A (en) * | 1993-01-27 | 1994-05-24 | Monsanto Company | Urea derivatives useful as platelet aggregation inhibitors |
DE4309867A1 (de) | 1993-03-26 | 1994-09-29 | Cassella Ag | Neue Harnstoffderivate, ihre Herstellung und Verwendung |
ES2160626T3 (es) | 1993-04-09 | 2001-11-16 | Toyama Chemical Co Ltd | Inmunomodulador, inhibidor de la adherencia celular, y agente que permite tratar y prevenir enfermedades autoinmunes. |
US5770573A (en) * | 1993-12-06 | 1998-06-23 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
AU693143B2 (en) | 1993-12-06 | 1998-06-25 | Cytel Corporation | CS-1 peptidomimetics, compositions and methods of using the same |
US5434188A (en) | 1994-03-07 | 1995-07-18 | Warner-Lambert Company | 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV |
US6248713B1 (en) * | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
US6239108B1 (en) * | 1996-07-11 | 2001-05-29 | Biogen, Inc. | Cell adhesion inhibitors |
-
1995
- 1995-07-11 US US08/498,237 patent/US6248713B1/en not_active Expired - Fee Related
-
1996
- 1996-07-11 RO RO98-00033A patent/RO121032B1/ro unknown
- 1996-07-11 CA CA002226868A patent/CA2226868A1/en not_active Abandoned
- 1996-07-11 CZ CZ0005298A patent/CZ299054B6/cs not_active IP Right Cessation
- 1996-07-11 DE DE69637328T patent/DE69637328T2/de not_active Expired - Fee Related
- 1996-07-11 TR TR1998/00028T patent/TR199800028T1/xx unknown
- 1996-07-11 HU HU9802202A patent/HUP9802202A3/hu unknown
- 1996-07-11 EP EP96924444A patent/EP0842196B1/en not_active Expired - Lifetime
- 1996-07-11 BR BR9609782A patent/BR9609782A/pt not_active Application Discontinuation
- 1996-07-11 PL PL96324491A patent/PL188446B1/pl not_active IP Right Cessation
- 1996-07-11 NZ NZ312950A patent/NZ312950A/xx unknown
- 1996-07-11 EE EEP200200384A patent/EE200200384A/xx unknown
- 1996-07-11 EA EA199800119A patent/EA001594B1/ru not_active IP Right Cessation
- 1996-07-11 IL IL12278396A patent/IL122783A/xx not_active IP Right Cessation
- 1996-07-11 WO PCT/US1996/011570 patent/WO1997003094A1/en active IP Right Grant
- 1996-07-11 CN CNB961963808A patent/CN1195778C/zh not_active Expired - Fee Related
- 1996-07-11 SK SK37-98A patent/SK3798A3/sk unknown
- 1996-07-11 EA EA200100103A patent/EA003737B1/ru not_active IP Right Cessation
- 1996-07-11 JP JP9505989A patent/JPH11511124A/ja not_active Ceased
- 1996-07-11 EE EE9700362A patent/EE03694B1/xx not_active IP Right Cessation
- 1996-07-11 AU AU64894/96A patent/AU716276B2/en not_active Ceased
- 1996-07-11 KR KR1019980700228A patent/KR100531586B1/ko not_active IP Right Cessation
- 1996-07-12 TW TW085108493A patent/TW570927B/zh not_active IP Right Cessation
- 1996-11-07 UA UA98020687A patent/UA71888C2/uk unknown
-
1998
- 1998-01-08 IS IS4648A patent/IS4648A/is unknown
- 1998-01-09 NO NO980097A patent/NO980097L/no unknown
- 1998-01-09 FI FI980033A patent/FI980033A/fi unknown
- 1998-01-12 MX MX9800348A patent/MX9800348A/es not_active IP Right Cessation
- 1998-02-10 BG BG102241A patent/BG63876B1/bg unknown
- 1998-11-20 HK HK98112181A patent/HK1010888A1/xx not_active IP Right Cessation
-
2000
- 2000-01-13 US US09/482,296 patent/US6596687B1/en not_active Expired - Fee Related
-
2007
- 2007-09-13 JP JP2007238556A patent/JP2008088171A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1010888A1 (en) | Cell adhesion inhibitors | |
AU4269896A (en) | Fibronectin adhesion inhibitors | |
GR3033293T3 (en) | Cyclic adhesion inhibitors | |
EP0835109A4 (en) | PYRIDINONE-BASED THROMBIN INHIBITORS | |
IL112756A0 (en) | Sulfated alfa-glycolipid derivatives as cell adhesion inhibitors | |
PL321759A1 (en) | Novel thrombosin inhibitors | |
IL125126A (en) | Electroconversion cell | |
GB9611422D0 (en) | Coated scale inhibitors | |
IL127563A0 (en) | Cell adhesion inhibiting compounds | |
EP0743951A4 (en) | SUBSTITUTED LACTOSE DERIVATIVES AS CELL ADHESION INHIBITORS | |
HUP9903631A3 (en) | Adhesion inhibitors | |
AU1868195A (en) | Cell signaling inhibitors | |
GB9502985D0 (en) | Enzyme inhibitors | |
AU6049796A (en) | Lysyloxidase inhibitors | |
ZA951144B (en) | Sulfated beta-glycolipid derivatives cell adhesion inhibitors | |
EP0810677A4 (en) | LOW THICKNESS BATTERY | |
SI0805796T1 (en) | Cell adhesion inhibitors | |
AU6860296A (en) | Cycloanthelmintic inhibitors | |
GB9516446D0 (en) | Icing inhibitors | |
IL110221A0 (en) | Peptide inhibitors of cell adhesion | |
ZA944921B (en) | Peptide inhibitors of cell adhesion | |
AU682036B2 (en) | Peptide inhibitors of cell adhesion | |
GB9500553D0 (en) | Enzyme inhibitors | |
GB9509774D0 (en) | Enzyme inhibitors | |
GB9508432D0 (en) | Corrosion inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20120711 |